AI algorithms and mRNA display technologies are accelerating the discovery of cyclic peptide therapeutics, enabling the identification of candidates with drug-like properties for challenging targets. These technologies are transforming the peptide drug discovery landscape, making it faster, more efficient, and more successful.
mRNA display is a powerful technique for discovering cyclic peptides that bind to specific targets. The technology involves generating large libraries of cyclic peptides (up to 10^12-10^14 members) and selecting those that bind to the target of interest. The selected peptides are then identified by sequencing the mRNA that encodes them. This approach enables the discovery of high-affinity binders for targets that are difficult to drug with small molecules.
AI is being integrated into cyclic peptide discovery in multiple ways. Generative AI models can propose novel cyclic peptide sequences with predicted target binding. Machine learning can analyze selection data to identify sequence motifs that contribute to binding. AI can also predict the properties of cyclic peptides, including stability, permeability, and bioavailability.
Recent advances in AI-driven peptide design are accelerating the discovery of peptide-based drugs with enhanced stability, specificity, and clinical potential[reference:120]. Generative AI approaches are being developed for peptide antibiotic optimization, enabling the design of antimicrobial peptides with improved properties[reference:121].
The combination of mRNA display and AI is creating new opportunities for cyclic peptide drug discovery. These technologies enable the rapid identification of lead candidates for challenging targets, reducing the time and cost of drug discovery. At PeptideHub, we support cyclic peptide discovery with custom synthesis of identified candidates, enabling rapid progression from discovery to development.